Published

458. Microdoses of Psilocybin Combined With Eugenol are Absorbed and Induce Unique Cerebellar Gene Expression

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Biological Psychiatry
Date: 2025-04-09
Source: OpenAlex
DOI: 10.1016/j.biopsych.2025.02.696
PubMed: Unavailable

Authors

Chuck T. Chen Aidan D Tyrrell Darryl Hudson Ralph Landau Adam H. Metherel Richard P. Bazinet

Watch author

Derived topics and classifications

psilocybin Pharmacology Microdosing Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

458. Microdoses of Psilocybin Combined With Eugenol are Absorbed and Induce Unique Cerebellar Gene Expression2025-04-09

Related papers

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto RatsPsychedelic Medicine · 2025-12-16 ‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injuryInternal Medicine Journal · 2026-01-01 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 “To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group TherapyPsychedelic Medicine · 2025-08-25 The Rise of Psilocybin Use in the United States: A Multisource Observational Study.Annals of internal medicine · 2025-07-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30